The Intestinal Microbiome: Relationship to Type 1 Diabetes
ABSTRACT This article discusses recent evidence that associates the developing intestinal microbiome to the pathogenesis of autoimmune T1D. It attempts to identify avenues that should be pursued that relate this new evidence to interventions that eventually could result in prevention.
- SourceAvailable from: Bruce A Vallance
[Show abstract] [Hide abstract]
- "It has been hypothesized that beneficial microbes or probiotics can protect against diabetes ( Neu et al . , 2010 ) . VSL#3 has been shown to prevent diabetes in NOD mice when administered after weaning ( Calcinaro et al . , 2005 ) . Yet , admin - istration to germ - free NOD neonatal mice shows no effect ( Yurkovetskiy et al . , 2013 ) . Although NOD mice were deficient in several beneficial microbes present in the probiotic VSL#3 , we found that "
ABSTRACT: Accumulating evidence supports that the intestinal microbiome is involved in Type 1 diabetes (T1D) pathogenesis through the gut-pancreas nexus. Our aim was to determine whether the intestinal microbiota in the non-obese diabetic (NOD) mouse model played a role in T1D through the gut. To examine the effect of the intestinal microbiota on T1D onset, we manipulated gut microbes by: (1) the fecal transplantation between non-obese diabetic (NOD) and resistant (NOR) mice and (2) the oral antibiotic and probiotic treatment of NOD mice. We monitored diabetes onset, quantified CD4+T cells in the Peyer's patches, profiled the microbiome and measured fecal short-chain fatty acids (SCFA). The gut microbiota from NOD mice harbored more pathobionts and fewer beneficial microbes in comparison with NOR mice. Fecal transplantation of NOD microbes induced insulitis in NOR hosts suggesting that the NOD microbiome is diabetogenic. Moreover, antibiotic exposure accelerated diabetes onset in NOD mice accompanied by increased T-helper type 1 (Th1) and reduced Th17 cells in the intestinal lymphoid tissues. The diabetogenic microbiome was characterized by a metagenome altered in several metabolic gene clusters. Furthermore, diabetes susceptibility correlated with reduced fecal SCFAs. In an attempt to correct the diabetogenic microbiome, we administered VLS#3 probiotics to NOD mice but found that VSL#3 colonized the intestine poorly and did not delay diabetes. We conclude that NOD mice harbor gut microbes that induce diabetes and that their diabetogenic microbiome can be amplified early in life through antibiotic exposure. Protective microbes like VSL#3 are insufficient to overcome the effects of a diabetogenic microbiome.The ISME Journal advance online publication, 14 August 2015; doi:10.1038/ismej.2015.114.The ISME Journal 08/2015; DOI:10.1038/ismej.2015.114 · 9.27 Impact Factor
[Show abstract] [Hide abstract]
- "is rapidly gaining importance in clinical research        , environmental studies    and biotechnology   . Numerous complex and reliable methods have been published for the phylogenetic identification of non-cloned short DNA reads from environmental or clinical samples, for example, the similarity-based methods MEGAN    and MG-RAST  , the marker-gene identifying phylogenetic analyzer AMPHORA  and its more user-friendly versions, AMPHORA2  and AmphoraNet  . "
ABSTRACT: Discoveries of new biomarkers for frequently occurring diseases are of special importance in today's medicine. While fully developed type II diabetes (T2D) can be detected easily, the early identification of high risk individuals is an area of interest in T2D, too. Metagenomic analysis of the human bacterial flora has shown subtle changes in diabetic patients, but no specific microbes are known to cause or promote the disease. Moderate changes were also detected in the microbial gene composition of the metagenomes of diabetic patients, but again, no specific gene was found that is present in disease-related and missing in healthy metagenome. However, these fine differences in microbial taxon- and gene composition are difficult to apply as quantitative biomarkers for diagnosing or predicting type II diabetes. In the present work we report some nucleotide 9-mers with significantly differing frequencies in diabetic and healthy intestinal flora. To our knowledge, it is the first time such short DNA fragments have been associated with T2D. The automated, quantitative analysis of the frequencies of short nucleotide sequences seems to be more feasible than accurate phylogenetic and functional analysis, and thus it might be a promising direction of diagnostic research.
[Show abstract] [Hide abstract]
- "All environmental factors potentially involved in the occurrence of obesity, T2DM, insulin resistance Fetal malnutrition during pregnancy   EDCs [76,80–85,87–89] Prenatal exposure to air pollution    T2DM  Insulin resistance    Acute pancreatitis Obesity   Alcohol, current tobacco use  Hypertryglyceridemia  Organophosphorus pesticides      Hypercalcemia  Anticholinesterase insecticides   Gallstones, biliary sludge   Glyphosate  Organic solvents, pentachlorophenol   Chronic pancreatitis Obesity   Alcohol, current tobacco use  Celiac diasease  Occupational chemicals    Nutritional factors and rare metabolic factors  Pancreatic cancer Obesity [8,111–114,119,121,123,124] Current tobacco use  Chronic pancreatitis  Alcohol  Diabetes  Residence close to metal industries  Inherited familial disorders   POPs      Long-life duration of obesity  Arsenic     Insulin resistance   Cadmium [171,169,172–175,123] Insulin-like growth factors and adipokines   Lead  Fatty pancreas  Pancreatic islet/β-cell damage and dysfunction Nutritional conditions  Particulates of less than 10 μm (PM10) Maternally derived gut microbiota  Nitrogen oxides, non-methane organic volatile compounds (VOCs)  Variations of intestinal microbiota   Bisphenol-A, phthalate     Ozone and sulfate  Nitrates, nitrites, N-nitroso compounds, persistent organochlorine pollutants   Chromium  Lead  EDCs, endocrine disrupting chemicals; POPs, persistent organic pollutants; T2DM, type 2 diabetes mellitus. rat F1 female offspring. "
ABSTRACT: The worldwide obesity epidemic is paralleled by a rise in the incidence of pancreatic disorders ranging from "fatty" pancreas to pancreatitis and cancer. Body fat accumulation and pancreatic dysfunctions have common pathways, mainly acting through insulin resistance and low-grade inflammation, frequently mediated by the epigenome. These mechanisms are affected by lifestyle and by the toxic effects of fat and pollutants. An early origin is common, starting in pediatric age or during the fetal life in response to nutritional factors, endocrine disruptor chemicals (EDCs) or parental exposure to toxics. A "fatty pancreas" is frequent in obese and is able to induce pancreatic damage. The fat is a target of EDCs and of the cytotoxic/mutagenic effects of heavy metals, and is the site of bioaccumulation of lipophilic and persistent pollutants related with insulin resistance and able to promote pancreatic cancer. Increased Body Mass Index (BMI) can act as independent risk factor for a more severe course of acute pancreatitis and obesity is also a well-known risk factor for pancreatic cancer, that is related with BMI, insulin resistance, and duration of exposure to the toxic effects of fat and/or of environmental pollutants. All these mechanisms involve gene-environment interactions through epigenetic factors, and might be manipulated by primary prevention measures. Further studies are needed, pointing to better assess the interplays of modifiable factors on both obesity and pancreatic diseases, and to verify the efficacy of primary prevention strategies involving lifestyle and environmental exposure to toxicsEuropean Journal of Internal Medicine 12/2014; 25(10):865-873. DOI:10.1016/j.ejim.2014.10.012 · 2.30 Impact Factor